Immunocore Holdings PLC (fra:6YG) Share Price

Company Profile

Business description
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Contact
92 Park Drive
Milton Park
AbingdonOxfordshireOX14 4RY
GBR
T: +44 1235438600
E: [email protected]
https://www.immunocore.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
524

Recommended

We revisit our long-term earnings assumptions and thesis.

Esther Holloway | 29 July 2026

Higher gold prices boosted profit yet shares remain materially overvalued.

Jon Mills, CFA | 29 July 2026

Near-term hurdles, long-term upside.

Mark Taylor | 28 July 2026

Index	Last price	Change	% Change
All Ordinaries	9,209.20	40.20	0.44%
CAC 40	8,458.78	52.72	0.63%
DAX 40	25,464.01	102.98	0.41%
Dow JONES (US)	52,747.32	537.24	1.03%
FTSE 100	10,871.02	89.27	0.83%
HKSE	25,674.53	363.68	1.44%
NASDAQ	24,876.91	55.17	-0.22%
Nikkei 225	61,689.86	675.06	-1.08%
NZX 50 Index	13,973.57	111.64	0.81%
S&P 500	7,428.78	15.60	0.21%
S&P/ASX 200	9,045.90	42.40	0.47%
SSE Composite Index	3,795.34	17.97	-0.47%